Recombinant Peptides in Thrombolysis

ABSTRACT

Recombinant thrombolytic peptides are mainly represented by recombinant forms of tissue plasminogen activator (t-PA), a proteolytic enzyme that catalyzes the conversion of plasminogen into active plasmin, which then functions to dissolve clots. The three clinically relevant recombinant thrombolytic peptides are alteplase (t-PA), reteplase (r-PA), and tenecteplase (TNK). r-PA and TNK have been structurally modified from native t-PA to increase their half-life and fibrin specificity. Thrombolytics play an important role in several diseases, including ST-segment elevation myocardial infarction (STEMI), deep vein thrombosis (DVT) and pulmonary embolism (PE), ischemic stroke, and peripheral arterial disease. Thrombolytic therapy has evolved into an alternative treatment for STEMI, reserved predominantly for patients who do not have access to timely percutaneous coronary intervention. In patients with DVT/PE or arterial related critical limb ischemia, the use of thrombolytic therapy is limited to specific patient populations. Thrombolytic therapy is the treatment of choice for ischemic stroke in patients who present ≤3 hours following the onset of symptoms. Moreover, thrombolytic therapy is used to restore function to stenotized central venous access devices as well as occluded hemodialysis access grafts.

KEYWORDS

Recombinant peptides - thrombolytic therapy - plasminogen activators - fibrinolysis - fibrinolytic agents

REFERENCES

• 1 Collen D, Lijnen H R. Thrombolytic agents.  Thromb Haemost. 2005;  93(4) 627-630
• 2 Todd J L, Tapson V F. Thrombolytic therapy for pulmonary embolism: a critical appraisal.  Chest. 2009;  135 1321-1329
• 3 Collen D, Lijnen H R. Basic and clinical aspects of fibrinolysis and thrombolysis.  Blood. 1991;  78(12) 3114-3124
• 4 Kunamneni A, Abdelghani T TA, Ellaiah P. Streptokinase—the drug of choice for thrombolytic therapy.  J Thromb Thrombolysis. 2007;  23(1) 9-23
• 5 Gibler W B. ST-segment elevation myocardial infarction (STEMI): decreasing the time to treatment in the ED. Emergency Medicine Cardiac Research and Education Group. 2007;1:1–4. Available at: http://www.emcreg.org/pdf/monographs/Time2Tx.pdf Accessed May 12, 2010
• 6 Keeley E C, Boura J A, Grines C L. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials.  Lancet. 2003;  361(9351) 13-20
• 7 Dalby M, Bouzamondo A, Lechat P, Montalescot G. Transfer for primary angioplasty versus immediate thrombolysis in acute myocardial infarction: a meta-analysis.  Circulation. 2003;  108(15) 1809-1814
• 8 Di Mario C, Dudek D, Piscione F CARESS-in-AMI (Combined Abciximab RE-teplase Stent Study in Acute Myocardial Infarction) Investigators et al. Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial.  Lancet. 2008;  371(9612) 559-568
• 9 Cantor W J, Fitchett D, Borgundvaag B TRANSFER-AMI Trial Investigators et al. Routine early angioplasty after fibrinolysis for acute myocardial infarction.  N Engl J Med. 2009;  360(26) 2705-2718
• 10 Bøhmer E, Hoffmann P, Abdelnoor M, Arnesen H, Halvorsen S. Efficacy and safety of immediate angioplasty versus ischemia-guided management after thrombolysis in acute myocardial infarction in areas with very long transfer distances results of the NORDISTEMI (NORwegian study on DIstrict treatment of ST-elevation myocardial infarction).  J Am Coll Cardiol. 2010;  55(2) 102-110
• 11 U.S. Department of Health and Human Services .The Surgeon General's call to action to prevent deep vein thrombosis and pulmonary embolism. 2008. Available at: http://www.surgeongeneral.gov/topics/deepvein/calltoaction/call-to-action-on-dvt-2008.pdf Accessed January 9, 2010
• 12 Kearon C, Kahn S R, Agnelli G et al.. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition).  Chest. 2008;  133(6, Suppl) 454S-545S
• 13 Nazir S A, Ganeshan A, Nazir S, Uberoi R. Endovascular treatment options in the management of lower limb deep venous thrombosis.  Cardiovasc Intervent Radiol. 2009;  32(5) 861-876
• 14 Chang R, Chen C C, Kam A, Mao E, Shawker T H, Horne III M K. Deep vein thrombosis of lower extremity: direct intraclot injection of alteplase once daily with systemic anticoagulation—results of pilot study.  Radiology. 2008;  246(2) 619-629
• 15 Kahn S R. The post-thrombotic syndrome: the forgotten morbidity of deep venous thrombosis.  J Thromb Thrombolysis. 2006;  21(1) 41-48
• 16 Arko F R, Davis III C M, Murphy E H et al.. Aggressive percutaneous mechanical thrombectomy of deep venous thrombosis: early clinical results.  Arch Surg. 2007;  142(6) 513-518; discussion 518-519
• 17 Dong B R, Hao Q, Yue J, Wu T, Liu G J. Thrombolytic therapy for pulmonary embolism.  Cochrane Database of Systematic Reviews. 2009;  (3) CD004437
• 18 Wan S, Quinlan D J, Agnelli G, Eikelboom J W. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials.  Circulation. 2004;  110(6) 744-749
• 19 ClinicalTrials.gov . PEITHO Pulmonary Embolism Thrombolysis Study.  Available at: http://clinicaltrials.gov/ct2/show/NCT00639743 Accessed January 11, 2010; 
• 20 Albers G W, Amarenco P, Easton J D, Sacco R L, Teal P. American College of Chest Physicians . Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition).  Chest. 2008;  133(6, Suppl) 630S-669S
• 21 van den Berg J S, de Jong G. Why ischemic stroke patients do not receive thrombolytic treatment: results from a general hospital.  Acta Neurol Scand. 2009;  120(3) 157-160
• 22 Hacke W, Kaste M, Bluhmki E ECASS Investigators et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.  N Engl J Med. 2008;  359(13) 1317-1329
• 23 Del Zoppo G J, Saver J L, Jauch E C, Adams Jr H P. American Heart Association Stroke Council . Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association.  Stroke. 2009;  40(8) 2945-2948
• 24 Current Controlled Trials Ltd. The Third International Stroke Trial (IST-3) of thrombolysis for acute ischaemic stroke. Available at: http://www.controlled-trials.com/ISRCTN257655182010 Accessed January 3, 2010
• 25 Gralla J, Brekenfeld C, Arnold M, Schroth G. Acute stroke: present and future of catheter-based interventions.  Herz. 2008;  33(7) 507-517
• 26 American Heart Association .Heart disease and stroke statistics: 2009 at-a-glance. 2009. Available at: http://www.americanheart.org/downloadable/heart/1240250946756LS-1982%20Heart%20and%20Stroke%20Update.042009.pdf Accessed January 12, 2010
• 27 Nichol G, Stiell I G, Laupacis A, Pham B, De Maio V J, Wells G A. A cumulative meta-analysis of the effectiveness of defibrillator-capable emergency medical services for victims of out-of-hospital cardiac arrest.  Ann Emerg Med. 1999;  34(4 Pt 1) 517-525
• 28 Böttiger B W, Arntz H R, Chamberlain D A TROICA Trial Investigators et al. Thrombolysis during resuscitation for out-of-hospital cardiac arrest.  N Engl J Med. 2008;  359(25) 2651-2662
• 29 Böttiger B W, Bode C, Kern S et al.. Efficacy and safety of thrombolytic therapy after initially unsuccessful cardiopulmonary resuscitation: a prospective clinical trial.  Lancet. 2001;  357(9268) 1583-1585
• 30 Hirsch A T, Haskal Z J, Hertzer N R American Association for Vascular Surgery et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic).  Circulation. 2006;  113(11) e463-e654
• 31 Diffin D C, Kandarpa K. Assessment of peripheral intraarterial thrombolysis versus surgical revascularization in acute lower-limb ischemia: a review of limb-salvage and mortality statistics.  J Vasc Interv Radiol. 1996;  7(1) 57-63
• 32 Almahameed A, Bhatt D L. Contemporary management of peripheral arterial disease: III. Endovascular and surgical management.  Cleve Clin J Med. 2006;  73(suppl 4) S45-S51
• 33 Ponec D, Irwin D, Haire W D et al.. Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial—the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial.  J Vasc Interv Radiol. 2001;  12(8) 951-955
• 34 Semba C P, Deitcher S R, Li X, Resnansky L, Tu T, McCluskey E R. Cardiovascular thrombolytic to Open Occluded Lines Investigators . Treatment of occluded central venous catheters with alteplase: results in 1,064 patients.  J Vasc Interv Radiol. 2002;  13(12) 1199-1205
• 35 Hilleman D E, Dunlay R W, Packard K A. Reteplase for dysfunctional hemodialysis catheter clearance.  Pharmacotherapy. 2003;  23(2) 137-141
• 36 Vogel P M, Bansal V, Marshall M W. Thrombosed hemodialysis grafts: lyse and wait with tissue plasminogen activator or urokinase compared to mechanical thrombolysis with the Arrow-Trerotola Percutaneous Thrombolytic Device.  J Vasc Interv Radiol. 2001;  12(10) 1157-1165
• 37 Clinical pharmacology. Available at: http://www.clinicalpharmacology-ip.com/Default.aspx Accessed January 11, 2010
• 38 Micromedex healthcare series. Available at: http://www.thomsonhc.com/hcs/librarian Accessed January 11, 2010
• 39 Antman E M, Anbe D T, Armstrong P W et al.. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction).  J Am Coll Cardiol. 2004;  44(3) E1-E211
• 40 Grines C L, Westerhausen Jr D R, Grines L L Air PAMI Study Group et al. A randomized trial of transfer for primary angioplasty versus on-site thrombolysis in patients with high-risk myocardial infarction: the Air Primary Angioplasty in Myocardial Infarction study.  J Am Coll Cardiol. 2002;  39(11) 1713-1719
• 41 Bonnefoy E, Lapostolle F, Leizorovicz A Comparison of Angioplasty and Prehospital Thromboysis in Acute Myocardial Infarction study group et al. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study.  Lancet. 2002;  360(9336) 825-829
• 42 Andersen H R, Nielsen T T, Rasmussen K DANAMI-2 Investigators et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction.  N Engl J Med. 2003;  349(8) 733-742
• 43 Vermeer F, Oude Ophuis A J, vd Berg E J et al.. Prospective randomised comparison between thrombolysis, rescue PTCA, and primary PTCA in patients with extensive myocardial infarction admitted to a hospital without PTCA facilities: a safety and feasibility study.  Heart. 1999;  82(4) 426-431
• 44 Widimský P, Groch L, Zelízko M, Aschermann M, Bednár F, Suryapranata H. Multicentre randomized trial comparing transport to primary angioplasty vs. immediate thrombolysis vs. combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory. The PRAGUE study.  Eur Heart J. 2000;  21(10) 823-831
• 45 Widimský P, Budesínský T, Vorác D ‘PRAGUE’ Study Group Investigators et al. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial—PRAGUE-2.  Eur Heart J. 2003;  24(1) 94-104